高级检索
当前位置: 首页 > 详情页

Association between overexpression of Wip1 and prognosis of patients with non-small cell lung cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Dept Oncol, 361 East Zhongshan Rd, Shijiazhuang 050011, Hebei, Peoples R China [2]Hebei Chest Hosp, Res Ctr Hebei Lung Canc Prevent & Treatment, Dept Lung Oncol, Shijiazhuang 050041, Hebei, Peoples R China [3]Hebei Chest Hosp, Res Ctr Hebei Lung Canc Prevent & Treatment, Dept Pathol, Shijiazhuang 050041, Hebei, Peoples R China [4]Hebei Med Univ, Hosp 4, Dept Oncol, Shijiazhuang 050012, Hebei, Peoples R China
出处:
ISSN:

关键词: wild-type p53-induced phosphatase 1 lung cancer non-small cell lung carcinoma prognosis

摘要:
Wild-type p53-induced phosphatase 1 (Wip1), also termed PPM1D, is a member of the protein phosphatase 2C family, which is characterized by distinctive oncogenic properties. Overexpression of Wip1 is observed in certain types of human tumors that are associated with significantly poor prognosis. The present study aimed to detect the expression of Wip1 in non-small cell lung cancer (NSCLC) and to analyze its prognostic value in such patients. The protein expression level of Wip1 was compared between NSCLC and normal lung tissue specimens using by immunohistochemistry, and it was found that Wip1 was highly expressed in NSCLCs but was absent or weakly expressed in normal lung tissues. Detailed clinical and demographic information of patients were retrospectively collected pre- and postoperatively, and Kaplan-Meier survival and Cox's regression analyses were performed to evaluate the prognosis of patients. Survival analysis revealed that the overall survival rate for patients in the Wip1-positive expression group was significantly lower than that of the Wip1-negative group, and Cox multivariate analysis indicated that positive Wip1 expression, pN classification and pathological stage were significant prognostic predictors. The results of the current study suggest that Wip1 may be associated with pathological diagnosis and prognostic evaluation of NSCLC.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2016]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2016]版:
Q4 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Dept Oncol, 361 East Zhongshan Rd, Shijiazhuang 050011, Hebei, Peoples R China [2]Hebei Chest Hosp, Res Ctr Hebei Lung Canc Prevent & Treatment, Dept Lung Oncol, Shijiazhuang 050041, Hebei, Peoples R China
通讯作者:
通讯机构: [1]Hebei Med Univ, Dept Oncol, 361 East Zhongshan Rd, Shijiazhuang 050011, Hebei, Peoples R China [4]Hebei Med Univ, Hosp 4, Dept Oncol, Shijiazhuang 050012, Hebei, Peoples R China [*1]Department of Oncology, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang, Hebei 050011, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号